登录 | 注册    关注公众号  
微信公众号
搜索
>产品&服务 > 抗Payload抗体——ADC PK研发核心工具

抗Payload抗体——ADC PK研发核心工具

抗Payload抗体——ADC PK研发核心工具
产品特征

高纯度:经SDS-PAGE及SEC-MALS验证>95%。

高灵敏度:经ADC药物结合验证。

高特异性:可特异性识别对应小分子毒素。

数据完善:提供完善的PK验证数据参考。

产品全面:提供裸抗、HRP标记、Biotin标记等多种形式,便于开发不同方法。

售后完善:可协助进行PK方法学建立。

应用场景

ADC药物临床前及临床阶段PK分析

背景
抗体偶联药物(ADC)由特异性抗体,小分子毒素(Payload)和连接子(Linker)三部分组成,其结构较传统小分子药物和抗体药物更 加复杂,药物异质性更高,因此其PK研究也更为复杂。 PK研究是对药物吸收、分布、代谢和排泄(ADME)时间过程的研究和表征。ADC药物的分析物通常包括总抗体(偶联和未偶联小分子 毒素的抗体)、药物偶联抗体(至少偶联一个小分子毒素的抗体) 、抗体偶联药物、游离药物及其类似物。总抗体和药物偶联抗体通常使 用基于LBA(配体结合实验,Ligand Binding Assay)的ELISA(酶联免疫吸附测定,Enzyme-linked Immunosorbent Assay) 测定,偶联药物、游离药物及其分解代谢物通常用LC-MS(液相色谱-质谱法,Liquid Chromatograph Mass Spectrometer)来分析。
为了解决ADC药物PK分析中的挑战和难点,ACROBiosystems百普赛斯发布多种高质量、高亲和力的抗Payload抗体,可用于ADC进行临床前及临床阶段的PK检测,为提高ADC药物PK分析的准确性和可靠性提供了有力的支持和保障。

ADC分析物及典型分析方法

分析物类型 分析物详情 典型的分析方法
Total Antibody Conjugated, partially unconjugated, and fully unconjugated (DAR ≥ 0) Ligand Binding Assay
Conjugated Antibody Antibody with minimum DAR ≥ 1 Ligand Binding Assay
Antibody-conjugated Drug Total small-molecule drug conjugated to Antibody Affinity LC-MS / Ligand Binding Assay
Unconjugated Drug Small molecule drug not conjugated to antibody LC-MS
Total Drug Total unconjugated and conjugated Drug LC-MS

血清中ADC的不同LBA分析形式

血清中ADC的不同LBA分析形式

血清中ADC的不同LBA分析形式1

产品列表
分子 货号 产品描述 订购/预购
DM-1 DM1-BLY73 Biotinylated Monoclonal Anti-DM-1&DM-4 Antibody, Mouse IgG1 (MALS verified)

订购

DM-1 DM1-PLY73 HRP conjugated Monoclonal Anti-DM-1&DM-4 Antibody,Mouse IgG1

订购

DM-1 DM1-Y73 Monoclonal Anti-DM-1&DM-4 Antibody, Mouse IgG1 (MALS verified)

订购

DXD DXD-BVM807 Biotinylated Anti-DXD Antibody, Mouse IgG1, Avitag™ (MALS verified)

订购

DXD DXD-M684 Monoclonal Anti-DXD&Exatecan Antibody, Mouse IgG1 (MALS verified)

订购

DXD DXD-PLM684 HRP conjugated Monoclonal Anti-DXD&Exatecan Antibody, Mouse IgG1

订购

Eribulin ERN-BMY12b Biotinylated Rabbit Anti-Eribulin Antibody, Rabbit IgG (1M1G11)

订购

Eribulin ERN-MY2012b Monoclonal Anti-Eribulin Antibody, Rabbit IgG (1M1G11)

订购

Eribulin ERN-MY2063b Monoclonal Anti-Eribulin Antibody, Rabbit IgG (1M2B11)

订购

Eribulin ERN-PLM12b HRP conjugated Monoclonal Anti-Eribulin Antibody, Rabbit IgG (1M1G11)

订购

MMAE MME-BLS104 Biotinylated Monoclonal Anti-MMAE&MMAF Antibody, Mouse IgG1 (MALS verified)

订购

MMAE MME-M5252 Monoclonal Anti-MMAE&MMAF Antibody, Mouse IgG1 (MALS verified)

订购

MMAE MME-PLS104 HRP conjugated Monoclonal Anti-MMAE&MMAF Antibody,Mouse IgG1

订购

PTX PTX-S343 Monoclonal Anti-PTX Antibody, Mouse IgG2a (MALS verified)

订购

SN38 SN8-BVM808 Biotinylated Anti-SN38 Antibody, Mouse IgG1, Avitag™ (MALS verified)

订购

SN38 SN8-M685 Monoclonal Anti-SN38 Antibody, Mouse IgG1 (MALS verified)

订购

SN38 SN8-PLM685 HRP conjugated Monoclonal Anti-SN38 Antibody, Mouse IgG1

订购

ACROBiosystems正在积极开发更多高质量抗Payload抗体。如果您有任何建议或定制要求,请点此联系我们

点击申请抗Payload抗体试用装

验证数据

案例展示:PK方法开发与样品检测

包被抗DXD抗体,定量检测血清中T-Dxd浓度
包被抗DXD抗体,定量检测血清中T-Dxd浓度

Immobilized Mouse Anti-DXD&Exatecan Antibody, Mouse IgG1, mAb (Cat. No. DXD-M684) at 1 μg/mL, add Trastuzumab deruxtecan in the 50% Human serum and then add Biotinylated Human Her2, His,Avitag, premium grade (Cat. No. HE2-H82E2) at 0.5 μg/mL. Detection was performed using HRP-conjugated Streptavidin (Acro, Cat. No. STN-NH913) (Routinely tested).

申请 Protocol
包被HER2,Biotin标记抗DXD抗体作为二抗,定量检测血清中T-Dxd浓度
包被HER2,Biotin标记抗DXD抗体作为二抗,定量检测血清中T-Dxd浓度

Immobilized Human Her2, His Tag (Cat. No. HE2-H5225) at 1 μg/mL, add Trastuzumab Deruxtecan in the 100% Human Serum and then add Biotinylated Anti-DXD Antibody, Mouse IgG1, Avitag (Cat. No. DXD-BVM807) at 0.05 μg/mL. Detection was performed using HRP-conjugated Streptavidin (Acro, Cat. No. STN-NH913) (QC tested).

申请 Protocol
包被抗MMAE抗体,定量检测血清中RC48浓度
包被抗MMAE抗体,定量检测血清中RC48浓度

Immobilized Mouse Anti-MMAE&MMAF Antibody, Mouse IgG1 (Cat. No. MME-M5252) at 5 μg/mL, add Disitamab Vedotin (RC48) in the 50% Mouse serum and then add Biotinylated Human Her2, His,Avitag, premium grade (Cat. No. HE2-H82E2) at 0.5 μg/mL. Detection was performed using HRP-conjugated Streptavidin (Acro, Cat. No. STN-NH913) (Routinely tested).

申请 Protocol
包被抗DM1抗体,定量检测血清中Trastuzumab-DM1浓度
包被抗DM1抗体,定量检测血清中Trastuzumab-DM1浓度

Immobilized Monoclonal Anti-DM-1&DM-4 Antibody, Mouse IgG1 (Cat. No. DM1-Y73) at 5 μg/mL, add Trastuzumab-DM1 in the 50% Human serum and then add Biotinylated Human Her2, His,Avitag, premium grade (Cat. No. HE2-H82E2) at 0.5 μg/mL. Detection was performed using HRP-conjugated Streptavidin (Acro, Cat. No. STN-NH913) (Routinely tested).

申请 Protocol

高纯度经SEC-MALS验证

抗MMAE抗体,高纯度经MALS验证

The purity of Mouse Anti-MMAE Antibody, Mouse IgG1 (Cat. No. MME-M5252) is more than 90% and the molecular weight of this protein is around 134-163 kDa verified by SEC-MALS.

与ADC的高亲和力经ELISA验证

抗DXD 抗体高灵敏度结合DXD

抗DXD 抗体高灵敏度结合DXD

Immobilized ADC-DXD at 1 μg/mL (100 μL/well) can bind Mouse Anti-DXD&Exatecan Antibody, Mouse IgG1, mAb (Cat. No. DXD-M684) with a linear range of 0.1-4 ng/mL (Routinely tested).

申请 Protocol

抗MMAE抗体高灵敏度结合MMAE

抗MMAE抗体高灵敏度结合MMAE

Immobilized Disitamab Vedotin (RC48) at 0.2 μg/mL (100 μL/well) can bind Monoclonal Anti-MMAE&MMAF Antibody, Mouse IgG1 (Cat. No. MME-M5252) with a linear range of 0.1-2 ng/mL (QC tested).

申请 Protocol
Immobilized ADC-DM4 at 2 μg/mL (100 μL/well) can bind Monoclonal Anti-DM-1&DM-4 Antibody

Immobilized ADC-DM4 at 2 μg/mL (100 μL/well) can bind Monoclonal Anti-DM-1&DM-4 Antibody, Mouse IgG1 (Cat. No. DM1-Y73) with a linear range of 0.20-6.25ng/mL (Routinely tested).

申请 Protocol
Immobilized ADC-DXD at 1 μg/mL (100 μL/well) can bind HRP conjugated Mouse Anti-DXD&Exatecan Antibody

Immobilized ADC-DXD at 1 μg/mL (100 μL/well) can bind HRP conjugated Mouse Anti-DXD&Exatecan Antibody, Mouse IgG1 (Cat. No. DXD-PLM684) with a linear range of 0.5-31 ng/mL (Routinely tested).

申请 Protocol
抗独特型抗体及开发服务
抗独特型抗体(anti-idiotypic antibody)是能够识别另一抗体可变区,并产生特异性结合的抗体。抗独特型抗体在药物开发中的应用非常广泛,可以作为免疫原性(immunogenicity)分析的重要参照,同时也可以特异性检测体内抗体药水平,是药代动力学(pharmacokinetics)研究的重要试剂。
ACROBiosystems百普赛斯可向您提供一系列高亲和力、高特异性、高灵敏度的抗独特型抗体,用于成药性评估、PK研究、免疫原性分析。
抗独特型抗体
分子 货号 产品描述 中和活性 应用
Adalimu*ab ADB-Y19 Anti-Adalimu*ab Antibodies (AY19) Neutralizing Antibody ADA assay; Neutralizing assay; Indirect ELISA
Adalimu*ab ADB-Y23b Anti-Adalimu*ab Antibodies (AY23b) (recommended for PK/PD) Non-Neutralizing Antibody PK bridging ELISA; Indirect ELISA
Bevacizu*ab BEB-Y10 Anti-Bevacizu*ab Antibodies (AY10) (MALS verified, recommended for PK/PD) Neutralizing Antibody PK bridging ELISA; Neutralizing assay; Indirect ELISA
Bevacizu*ab BEB-Y12 Anti-Bevacizu*ab Antibodies (AY12) (recommended for neutralizing assay) Neutralizing Antibody ADA assay; Neutralizing assay; Indirect ELISA
Bevacizu*ab BEB-Y9 Anti-Bevacizu*ab Antibodies (AY9) (recommended for ADA assay) Neutralizing Antibody ADA assay; Neutralizing assay; Indirect ELISA
Bevacizu*ab BEB-BY13 Biotinylated Anti-Bevacizu*ab Antibodies (AY13) (recommended for PK/PD) Neutralizing Antibody PK bridging ELISA;Neutralizing assay; Indirect ELISA
Cetuxi*ab CEB-Y27 Anti-Cetuxi*ab Antibodies (AY27) (recommended for ADA assay) Neutralizing Antibody ADA assay; Neutralizing assay; Indirect ELISA
Cetuxi*ab CEB-Y31 Anti-Cetuxi*ab Antibodies (AY31) (Non-Neutralizing) Non-Neutralizing Antibody ADA assay; Indirect ELISA
Cetuxi*ab CEB-Y28 Anti-Cetuxi*ab Antibodies (AY28) Neutralizing Antibody ADA assay; Neutralizing assay; Indirect ELISA
Cetuxi*ab CEB-BY31 Biotinylated Anti-Cetuxi*ab Antibodies (AY31) (recommended for PK/PD) Non-Neutralizing Antibody PK bridging ELISA; Indirect ELISA
Rituxi*ab RIB-Y36 Anti-Rituxi*ab Antibodies (AY36) (recommended for ADA assay) Neutralizing Antibody ADA assay;Neutralizing assay; Indirect ELISA
Rituxi*ab RIB-Y37 Anti-Rituxi*ab Antibodies (AY37) (recommended for PK/PD) Neutralizing Antibody PK bridging ELISA;Neutralizing assay;Indirect ELISA
Rituxi*ab RIB-Y35c Anti-Rituxi*ab Antibodies (MALS verified) Non-Neutralizing Antibody ADA assay; Indirect ELISA
Trastuzu*ab TRB-Y5b Anti-Trastuzu*ab Antibodies (AY5b) (recommended for PK/PD) Neutralizing Antibody PK bridging ELISA
Trastuzu*ab TRB-Y1b Anti-Trastuzu*ab Antibodies (AY1b) (recommended for PK/PD) Neutralizing Antibody PK bridging ELISA; Neutralizing assay; Indirect ELISA
抗独特型抗体开发服务
同时为了满足客户多样化需求,还可提供从抗原制备到单克隆抗独特型抗体,多克隆抗独特型抗体,药代动力学及免疫原性检测试剂盒开发的一站式服务。
硬件实力

硬件实力
通过国际AAALAC认证
规范性管理和使用动物
保证抗体质量

经验丰富

经验丰富
专注抗独特型抗体开发
项目组一对一服务

一站式服务

一站式服务
从抗原制备到试剂盒开发

应用保证型服务

应用保证型服务
交付灵敏度满足法规要求

全球交付

全球交付
健全供应链体系
支持全球范围内临床试验

产品活动
点击申请抗Payload抗体试用装
ACRO质量管理体系

消息提示

请输入您的联系方式,再点击提交!

确定